Last reviewed · How we verify
Golimumab Prefilled Syringe
At a glance
| Generic name | Golimumab Prefilled Syringe |
|---|---|
| Sponsor | David Drobne |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis (PHASE4)
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
- REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) (PHASE4)
- Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients (PHASE3)
- Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria (PHASE3)
- Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Golimumab Prefilled Syringe CI brief — competitive landscape report
- Golimumab Prefilled Syringe updates RSS · CI watch RSS
- David Drobne portfolio CI